The Conversation (0)
Kiniksa Pharmaceuticals Announces Pricing of Initial Public Offering
May. 24, 2018 08:37AM PST
Pharmaceutical InvestingKiniksa Pharmaceuticals announced today the pricing of its initial public offering of 8,477,777 Class A common shares at a public offering price of $18.00 per share, before underwriting discounts and commissions. The gross proceeds to Kiniksa from this offering, before deducting underwriting discounts and commissions and estimated offering expenses, are expected to be approximately $152.6 …
Kiniksa Pharmaceuticals announced today the pricing of its initial public offering of 8,477,777 Class A common shares at a public offering price of $18.00 per share, before underwriting discounts and commissions. The gross proceeds to Kiniksa from this offering, before deducting underwriting discounts and commissions and estimated offering expenses, are expected to be approximately $152.6 million. In addition, Kiniksa has granted the underwriters a 30-day option to purchase up to 1,271,666 additional Class A common shares at the initial public offering price, less underwriting discounts and commissions.
As quoted in the press release:
The shares are expected to begin trading on The Nasdaq Global Select Market on May 24, 2018 under the ticker symbol “KNSA.” The offering is expected to close on May 29, 2018, subject to customary closing conditions. All of the Class A common shares are being offered by Kiniksa.
Goldman Sachs & Co. LLC and J.P. Morgan Securities, LLC are acting as joint book-running managers for the offering. JMP Securities LLC and Wedbush Securities Inc. are acting as co-managers for the offering.
